Actelion’s Opsumit Ramps Up As Tracleer Patent Loss Gets Closer

The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.